Sumitomo Chemical India Ltd

Meeting Details

• Date and time: 3 September 2026, 09:00 A.M. onwards.
• Type: 1x1 and group meetings.
• Organised by: Elara Capital.
• Location: Mumbai.
• Purpose: discussions based on publicly available information.
• Key company participants: management representatives.

Meeting Details

• Date: 19 August 2026; Time: 3:00 pm onwards; Group meeting in Mumbai; Organized by Motilal Oswal.

Participants

• Company officials will meet investors/analysts.

Purpose

• Discussions based on publicly available information; no UPSI intended.

Additional Notes

• Changes may occur due to host/company exigencies.

AGM Details

• Date: 27 July 2026; mode: virtual meeting via video conferencing.
• Shareholders on record date: 112060.
• Attendance: 1 promoter and 64 public shareholders attended via video conferencing.

Key Resolutions and Outcomes

• Resolution 1 (Ordinary): Adoption of Audited Financial Statements — Passed.
• Resolution 2 (Ordinary): Dividend of ₹1.30 per equity share — Passed; 9.74% against.
• Resolution 3 (Ordinary): Reappointment of Dr. Suresh Ramachandran — Passed; 10.96% against.
• Resolution 4 (Special): Reappointment of N. Sivaraman for 3 years from Sep 1, 2026 — Passed; 0.11% against.
• Resolution 5 (Special): Anand Mohan Tiwari appointed Independent Director for 2 years from Aug 31, 2026 — Passed.
• Resolution 6 (Ordinary): Chetan Shah appointed Non-Executive Non-Independent Director from Sep 1, 2026 — Passed.
• Resolution 7 (Special): Promote Suresh Ramachandran to Managing Director from Sep 1, 2026 — Passed.
• Resolution 8 (Ordinary): Advisory fees to Chetan Shah for year from Sep 1, 2026 — Passed; 0.0018% against.
• Resolution 9 (Special): Approval for material related party transactions with Sumitomo — Passed.
• Resolution 10 (Ordinary): Ratification of remuneration for Cost Auditors — Passed.

Governance and Related Actions

• MD appointment: Suresh Ramachandran as Managing Director from 1 Sep 2026.
• Independent Directors: N. Sivaraman reappointed for 3 years from Sep 1, 2026.
• Independent Directors: Anand Mohan Tiwari appointed for 2 years from 31 Aug 2026.
• Director: Chetan Shah appointed Non-Executive Non-Independent Director from Sep 1, 2026.
• Auditor matter: Cost Auditor remuneration ratification to GMVP & Associates LLP.

Business Overview

• Core business: crop protection products with generics and speciality offerings in India and exports to ~50 countries.
• Strategic objective: expand Make in India manufacturing and capacity expansion; broaden product portfolio.
• Leadership transition: MD moves to non-executive; board refresh and new independent directors planned.

Operational Highlights

• Q1FY27 revenue Rs 1,063 crore, up 1% YoY.
• Export revenue grew 26% YoY, now 16% of total.
• Gross margin 39.2%; EBITDA margin 21.9%.
• Insurance claim Rs 27 crore boosted PBT and PAT by ~20% YoY.
• Topgrain and Helibax to launch in Q2FY27.
• Q1FY27 net profit Rs 214.5 crore; margin 20.2%.
• FY26 revenue Rs 3,238.3 crore; EBITDA Rs 670.9 crore; PAT Rs 543.0 crore.
• Cash & cash equivalents end June 2026: Rs 2,549 crore.
• Net working capital days: 103; June 2026 receivable days 68, inventory 124, payables 77.

Financial Performance

• Q1FY27: Gross profit Rs 416.7 crore; gross margin 39.2%.
• Q1FY27: EBITDA Rs 233.3 crore; EBITDA margin 21.9%.
• PBT Rs 288.2 crore; PBT margin 27.1%.
• Tax Rs 73.7 crore; Net profit Rs 214.5 crore; net margin 20.2%.
• FY26: Revenue Rs 3,238.3 crore; EBITDA Rs 670.9 crore; PAT Rs 543.0 crore.
• FY26: EBITDA margin 20.7%; PAT margin 16.8%.
• Net revenue from operations for FY26-FY21 trend shown; RoCE ~20.7% in FY26.

Capital Structure & Liquidity

• Debt position: minimal borrowings (current 0.2 Cr; non-current 1.3 Cr as of Mar-26).
• Equity: Rs 3,393.8 crore; net worth Rs 3,394 crore (Mar-26).
• Cash & equivalents: Rs 2,549 crore as of 30 Jun 2026.
• Operating cash flow: Rs 445.5 crore; investing Rs -332.0 crore; financing Rs -82.9 crore;

Strategic Priorities & Outlook

• Invest ~15% of consolidated EBITDA annually in capacity upgrades.
• R&D integration with SCC units to improve yields and efficiency; new products.
• Expand exports to Africa, Latin America, Asia; leverage SCC global network.
• Launch multiple new products; off-patent and specialty lines; strong field marketing.
• Dahej hub development for high-potential patented molecules; capex Rs 150 crore.
• Tarapur capex for two molecules; payback <5 years; commercialization late FY2027-29.

Risks & Mitigation

• Domestic demand slow due to delayed monsoon; mitigated by price revisions and product mix.
• Export growth provides offset to domestic weakness; ongoing diversification across geographies.
• One-off insurance income (Rs 27 Cr) boosted near-term profitability; underlying trend remains robust.

Governance & Leadership

• MD to become Non-Executive Non-Independent from 1 Sep 2026; chairmanship under consideration.
• N. Sivaraman re-appointed Independent Director (Sep 2026–Aug 2029).
• Anand Mohan Tiwari appointed Independent Director (Aug 2026–Aug 2028).
• Dr. Suresh Ramachandran appointed Managing Director from 1 Sep 2026.
• Sushil Marfatia (Executive Director) and Ninad Gupte (Non-exec) terms end Aug 31, 2026.

AGM details

• AGM held on 27 July 2026 at 2:30 PM via VC/OAVM.
• Meeting commenced 2:30 PM and concluded 4:04 PM.
• Chairman: Dr. Mukul G. Asher.
• Quorum: 65 members attended.
• Electronic voting facility provided for all resolutions.

Resolutions presented

• Ordinary: Adoption of Audited Financial Statements and related reports.
• Ordinary: Declaration of dividend of 1.30 per equity share.
• Ordinary: Re-appointment of Dr. Suresh Ramachandran on retirement by rotation.
• Special: Reappointment of Mr. N. Sivaraman as Independent Director for three years from Sep 1, 2026.
• Special: Appointment of Mr. Anand Mohan Tiwari as Independent Director for two years from Aug 31, 2026.
• Special: Appointment of Independent Director with effect from 1 September 2026.
• Special: Promotion of Dr. Suresh Ramachandran to Managing Director from 1 Sep 2026.
• Special: Advisory, commission, and sitting fees payable to Mr. Chetan Shah from 1 Sep 2026 for one year.
• Ordinary: Approval for material related party transactions with Sumitomo Chemical Company Limited during FY 2026-27.
• Ordinary: Ratification of remuneration of M/s. GMVP & Associates LLP, Cost Auditors.

Voting results

• Voting results to be disseminated to stock exchanges and placed on the company website.

Dividend

• Dividend proposed/approved: ₹1.30 per equity share.

Directors & appointments

• Dr. Suresh Ramachandran reappointed as Director (rotational).
• Mr. N. Sivaraman reappointed as Independent Director for three years.
• Mr. Anand Mohan Tiwari appointed as Independent Director for two years.
• Promotion of Dr. Suresh Ramachandran to Managing Director from 1 Sep 2026.

Auditors

• Cost Auditor remuneration ratified: M/s. GMVP & Associates LLP.

Material related party transactions

• Material related party transactions with Sumitomo Chemical Company Limited approved for FY 2026-27.

Standalone results

• Revenue from operations ₹10,540.75 million; total income ₹11,011.38 million.
• PBT after exceptional items ₹2,912.61 million; tax ₹747.32 million; PAT ₹2,165.29 million.
• Insurance claim for business interruption ₹268.96 million; exceptional item.
• Labour-code impact ₹151.86 million; exceptional item (prior year).
• Basic/diluted EPS ₹4.34 for the quarter.
• Single reportable segment: agro-chemicals; no segment disclosure.
• Unaudited standalone results; board approved 27 July 2026.

Consolidated results

• Revenue from operations ₹10,633.46 million; total income ₹11,106.30 million.
• PBT after exceptional items ₹2,882.41 million; tax ₹737.27 million; PAT ₹2,145.14 million.
• Insurance claim for business interruption ₹268.96 million; exceptional item.
• Incremental labour-code impact ₹161.11 million; exceptional item.
• Basic/diluted EPS ₹4.30 for the quarter.
• Single reportable segment: agro-chemicals; no segment disclosure.
• Unaudited consolidated results; board approved 27 July 2026.

Resignation of Non-Executive Director

• Ninad D. Gupte resigns as Non-Executive, Non-Independent Director, effective 31 August 2026.
• Resignation cited personal reasons; no other material reasons disclosed.
• Directorship at Excel Industries Limited (Independent Director) with committee roles.

Results approved

• Unaudited standalone Q1 2026 results approved; revenue 10,540.75 million; PAT 2,165.29 million.
• Unaudited consolidated Q1 2026 results approved; revenue 10,633.46 million; PAT 2,145.14 million.
• Audit Committee reviewed both results prior to Board approval.
• Single reportable segment: agro-chemicals.

Key items and regulatory notes

• Insurance claim for business interruption of Rs 268.96 million recognised as an exceptional item.
• Standalone exceptional item: Rs 151.86 million due to new labour codes.
• Consolidated exceptional item: Rs 161.11 million due to labour codes.
• Glyphosate regulatory matter under Delhi High Court petitions; government stay until disposal.
• Auditors' limited review reports issued; results prepared per Ind AS 34; no material misstatement.
• Some subsidiary interim figures not reviewed; not material to the Group.

RTA and certificate basis

• Certificate from MUFG Intime India Private Limited (R&T Agent) supports dematerialisation actions.

Period covered

• Quarter ended 30 June 2026 covered by Reg 7(3) certificate.

Dematerialisation outcome

• Securities dematerialised were listed on exchanges and certificates cancelled after verification.

Reg 7(3) compliance confirmation

• Company confirms Reg 7(3) compliance based on RTA certificate.

Meeting Details

• Date of board meeting: 27 July 2026.
• Time of the meeting: Not disclosed.
• Location: Not disclosed.

Key Agenda Items

• Consider Standalone and Consolidated unaudited financial results for quarter ended 30 June 2026.

Other Notes

• No other material notes disclosed in the filing.